Please assess the completion status of the following clinical trial:

Trial Title: A Controlled Clinical Study of Dupilumab in Patients With Bilateral Nasal Polyps

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Participants with bilateral sinonasal polyposis that despite prior treatment with systemic corticosteroids (SCS) anytime within the past 2 years; and/or had a medical contraindication / intolerance to SCS; and/or had prior surgery for NP at the screening visit, had:~* An endoscopic bilateral NPS of at least 5 out of a maximum score of 8 (with a minimum score of 2 in each nasal cavity).~* Ongoing symptoms (for at least 8 weeks prior to Visit \[V\] 1) of nasal congestion/blockage/obstruction with moderate or severe symptom severity (score 2 or 3) at V1 and a weekly average severity of greater than 1 at the time of randomization (V2), and another symptom such as loss of smell, rhinorrhea (anterior/posterior).~* Signed written informed consent.~Exclusion criteria:~* Participants \<18 years of age.~* Participants who were previously treated in dupilumab studies.~* Participants who had taken:~* Biologic therapy/systemic immunosuppressant to treat inflammatory disease or autoimmune disease (eg, rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis, etc.) within 2 months before V1 or 5 half-lives, whichever was longer.~* Any experimental monoclonal antibody (mAB) within 5 half-lives or within 6 months before V1 if the half-life was unknown.~* Anti-immunoglobulin E (IgE) therapy (omalizumab) within 130 days prior to V1.~* Participants who received leukotriene antagonists/modifiers at V1 unless they were on a continuous treatment for at least 30 days prior to V1.~* Initiated allergen immunotherapy within 3 months prior to V1 or planned to begin therapy or changed its dose during the run-in period or the randomized treatment period.~* Participants who undergone any intranasal and/or sinus surgery (including polypectomy) within 6 months prior to V1.~* Participants who had a sinonasal or sinus surgery changing the lateral wall structure of the nose making impossible the evaluation of NPS.~* Participants with conditions/concomitant diseases making them nonevaluable at V1 or for the primary efficacy endpoint such as:~* Antrochoanal polyps;~* Nasal septal deviation that would occlude at least one nostril;~* Acute sinusitis, nasal infection or upper respiratory infection;~* Ongoing rhinitis medicamentosa;~* Allergic granulomatous angiitis (Churg-Strauss syndrome), granulomatosis with polyangiitis (Wegener's granulomatosis), Young's syndrome, Kartagener's syndrome or other dyskinetic ciliary syndromes, concomitant cystic fibrosis;~* Radiologic suspicion, or confirmed invasive or expansive fungal rhinosinusitis.~* Participants with nasal cavity malignant tumor and benign tumors (eg, papilloma, blood boil, etc).~* Participants with forced expiratory volume in 1 second (FEV1) 50% or less (of predicted normal).~* Participants who received concomitant treatment prohibited in the study.~* Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit.~* History of human immunodeficiency virus (HIV) infection or positive HIV serology at screening.~* Positive with hepatitis B surface antigen (HBsAg) or hepatitis C antibody at the screening visit.~* Active chronic or acute infection requiring systemic treatment within 2 weeks before the baseline visit.~* Known or suspected history of immunosuppression.~* Pregnant or breastfeeding women, or women planned to become pregnant or breastfeed during the study.~* Women unwilling to use adequate birth control, if of reproductive potential and sexually active.~The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (for dupilumab), 1 subcutaneous (SC) injection every 2 weeks (q2w) from Day 1 of Week 0 up to Week 24 added to background therapy of intranasal mometasone furoate nasal spray (MFNS) at stable dose.
- Dupilumab 300 mg (Type: EXPERIMENTAL): Dupilumab 300 mg SC injection q2w from Day 1 of Week 0 up to Week 24 added to background therapy of intranasal MFNS at stable dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).